Dr Neal Shore, Uro-Oncologist and Chief Medical Officer for Genesis Care and Urology and Surgical Oncology in the United States and Dr Elena Castro, Medical Oncologist at Hospital Universitario 12 de Octubre in Madrid, discuss clinical implementation of PARP inhibitor monotherapy for prostate cancer patients, providing both a US and EU perspective. In this podcast, the experts discuss the key efficacy and safety findings from the olaparib registration study, PROfound, and the TRITON-2 study which led to accelerated approval for rucaparib. They also discuss the recent data from the rucaparib confirmatory phase 3 trial, TRITON 3 and based on the results of these studies, debate are all PARP inhibitors the same and can the results be extrapolated from one PARP inhibitor to another. The timing of treatment with PARP inhibitors versus taxanes is also explored. Genetic testing is amongst the topics covered, including when to consider germline versus somatic testing and the impact of various homologous recombination repair alterations on efficacy.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related